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Demyelinating Disease in patients  
with myasthenia gravis
Denis Bernardi Bichuetti1,2, Tatiane Martins de Barros1,2, Enedina Maria Lobato Oliveira1,3,5,  
Marcelo Annes1,3, Alberto Alain Gabbai1,4
Abstract – Myasthenia gravis (MG) is an autoimmune disease characterized by fluctuating muscle weakness, 
caused by impaired neuromuscular transmission. Patients with MG can present other autoimmune diseases in 
association, commonly hypo or hyperthyroidism. The association of MG to demyelinating disease is rare and 
has been described before. We report on three Brazilian patients with MG that presented distinct demyelinating 
diseases, two monophasic and one recurrent neuromyelitis optica, several years after the diagnosis of MG, 
and discuss their clinical courses.
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Doenças desmielinizantes em pacientes com miastenia gravis
Resumo – Miastenia gravis (MG) é doença autoimune caracterizada por episódios de fraqueza muscular 
alternados com melhora, causada por bloqueio da junção neuromuscular. Pacientes com MG podem apresentar 
outras doenças autoimunes, comumente hipo ou hipertiroidismo, e a associação de MG com doenças 
desmielinizantes é raramente descrita. relatamos três pacientes brasileiros com MG que desenvolveram 
doenças desmielinizantes, dois monofásicos e um neuromielite óptica recorrente, vários anos após o 
diagnóstico de MG e discutimos seus cursos clínicos.
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Myasthenia gravis (MG) is an autoimmune disease 
characterized by fluctuating muscle weakness, caused 
by impaired neuromuscular transmission. Autoantibod-
ies specific for the human nicotinic acetylcholine recep-
tor are present in 70 to 80% of the patients, and the re-
maining cases can be associated with antibodies targeted 
at muscle specific kinase (MusK) and other proteins in the 
post-synaptic membrane1,2. MG has a bimodal incidence: 
(1) 20 to 40 years-old, predominated by women, and (2) 
60 to 80 years-old, predominated by men2.
Patients with MG commonly have thyroid disease and 
can present with nonspecific immune system abnormal-
ities, such as positive auto antibodies and alopecia area-
ta3-5. rarely, MG can be part of multiple autoimmune syn-
dromes, including autoimmune diabetes mellitus, throm-
botic thrombocytopenic purpura, sjögren syndrome, sys-
temic lupus erythematosus, vitiligo, among other rare dis-
eases5. In the past 20 years there has been an increasing 
number of reports on patients with MG presenting de-
myelinating diseases (dd)6-15, including multiple sclerosis, 
neuromyelitis optica (NMo), transverse myelitis and op-
tic neuritis. however, it is not known whether this associ-
ation is also part of unspecific immune activation, genet-
ic susceptibility or if it just happens by random. 
We herein describe three Brazilian patients with MG 
that presented different dd and discuss their clinical 
courses.
methoD
We reviewed the records of 630 patients followed for MG 
at the Neuroimmunology clinic of the Federal University of sao 
Paulo between 1979 and 2006. The diagnosis of MG was based 
on clinical history, neurological examination, electrophysiologi-
cal testing and response to acetyl cholinesterase inhibitor medi-
cation (pyridostigmine), assessed by a neurologist trained in neu-
romuscular diseases. rarely, patients were submitted to muscular 
biopsies to rule out other muscular conditions. Patients that pre-
sented with symptoms suggesting dd were selected for descrip-
tion. This review was approved by the Internal review Board (# 
0498/05) as part of an analysis of all patients with MG.
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results
We found three patients with MG that developed 
dd during follow-up; their clinical, electrophysiological 
and autoantibodies status are described in Tables 1 and 2. 
Briefly, patient 1 was diagnosed with generalized MG at 
the age of 26. Anti-thyroid antibodies were present (anti-
thyroid peroxidase and anti-tireoglobulin), but she nev-
er developed thyroid disease symptoms. she underwent 
thymectomy one year later and evolved asymptomatic on 
pyridostigmine treatment, thymus pathology disclosed 
lymphoid hyperplasia. At age 32, she presented mild trun-
cal and gait ataxia associated to bilateral horizontal nys-
tagmus. Brain magnetic resonance imaging (MrI) disclosed 
pons and cerebellum FlAIr and T2 hyperintense signal 
and mild gadolinium enhancement compatible with de-
myelination (Figure), cerebro-spinal fluid was normal. she 
was treated with 3g Iv methylprednisolone and symptoms 
resolved completely. MrI follow-up images disclosed res-
olution of the preview lesion and no new T2 or FlAIr ab-
normalities. she is currently on pyridostigmine for symp-
tomatic myasthenia control.
Patient 2 had intermittent diplopia since the age of 27 
and was further diagnosed with ocular myasthenia. he was 
initially treated with prednisone and pyridostigmine with 
mild response to treatment. Prednisone was switched to 
azathioprine due to hypertension, but symptoms only re-
solved when cyclosporine was started. At age 45 he devel-
oped pain, low visual acuity and ptosis in the left eye. Fun-
doscopic examination revealed a swollen disc on the left 
eye. MrI of the brain disclosed small unspecific periven-
tricular and subcortical white matter changes on T2 and 
FlAIr sequences. cyclosporine dose was raised and de-
flazacort introduced for symptomatic treatment of pto-
sis. symptoms resolved completely and his visual acuity 
returned to normal 2 months later.
Patient 3 was diagnosed with generalized MG at the 
age of 27 and underwent thymectomy one year after di-
agnosis. Four years later she presented with left side par-
esthesias and her spinal cord MrI disclosed a demyelin-
ating lesion from c5 to c7, absent cerebrospinal fluid oli-
goclonal bands and normal brain MrI. symptoms resolved 
after 3g Iv methylprednisolone. Two months later she de-
veloped bilateral acute visual loss that resolved within 30 
days. on first evaluation she had an atrophic optic disc 
on the left side, mild spastic gait and increased muscle 
stretch reflexes. A clinical diagnosis of neuromyelitis op-
tica was made based on the Wingerchuck criteria16 and 
she was started on azathioprine plus prednisone. during 
the next 2 years she presented with 1 myelitis and 2 optic 
neuritis relapses, treated with Iv methylprednisolone. An-
cillary test revealed an anti-nuclear-antibody (ANA) titer 
of 1/320. she recently became pregnant and stopped her 
medication, but her neurological exam discloses only mild 
Table 1. Myasthenia gravis clinical data.





1 F 26 25% neg yes Pyridostigmine neg
2 M 27 14.7% neg no deflazacort + cyclosporine + pyridostigmine neg
3 F 23 na na yes Azathioprine + prednisone + pyridostigmine* 1/320
na, not available; neg, negative; ANA, antinuclear antibodies; eNMG, electroneuromyography; *patient 3 is currently under no medication due to pregnancy.
Table 2. Demyelinating disease clinical data.
Patient Age of onset  
(years)
Time from MG 
to dd (years)
Presentation Follow-up MrI
1 32 6 Ataxia, vertigo and INo resoled with 3g methylprednisolone Brainstem
2 45 18 oN resolved spontaneously Unspecific
3 27 14 Myelitis evolved to recurrent NMo Myelitis c5-c7
MG, myasthenia gravis; dd, demyelinating disease; INo, internuclear ophtalmoplegia; NMo, neuromyelitis optica; oN, optic neuritis.
Figure. MRI of pa-
tient one after onset 
of symptoms. MRI 
FLAIR image of brain-
stem disclosing hy-
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low visual acuity without fatigue. data from her thymec-
tomy was unavailable from the other hospital.
Discussion
We report on a series of Brazilian patients that pre-
sented distinct dd 6-18 years after the diagnosis of MG. 
Two of them presented a monophasic course (patients 1 
and 2), one evolved to recurrent neuromyelitis optica (pa-
tient 3). The occurrence of dd in association to MG have 
been reported before, and are described as monophasic 
events (myelitis, acute disseminated encephalomyelitis 
and optic neuritis)10-13 and recurrent diseases (multiple 
sclerosis, recurrent transverse myelitis and NMo)7,9-12,14. 
some authors state that this association may not happen 
by chance, as the incidence of dd in patients with MG is 
much higher than expected in the general population6,15, 
and both may be part of multiple autoimmune syndromes 
or genetic predisposition to autoimmunity5.
recently, two reports have focused on this association. 
Gotkine et al.10 reported on 5 patients that presented dd 
after the diagnosis of MG, three had a monophasic event 
and two had a recurrent illness. The authors suggest that 
the association might be caused by subclinical systemic 
lupus erythematosus in three of them due to the presence 
of antinuclear antibodies, including both cases with recur-
rent dd, although this has been contested due to the fact 
that two of their patients could actually have NMo16-18. 
Kister et al.9 report on 4 patients that presented recurrent 
NMo years after undergoing thymectomy for MG. Two 
of these patients were positive for NMo-Ig antibodies in 
their serum18 and ANA and anti-GAd were also present in 
3 patients, disclosing systemic immune abnormalities. In 
both series, as in other cases reported before7,12-15 patients 
developed dd years after undergoing thymectomy, and 
the authors suggest that thymectomy might have induced 
immune dysregulation. Indeed, a long-term study of thy-
mectomized patients showed that a significant number of 
patients presented different autoantibodies in their serum 
years after thymectomy, 43% developed ANA positivity, 
12.5% of them developed autoimmune diseases, and more 
than 60% had at least 1 expansion within the cd8 and cd4 
T-cell repertoire, compared with non-thymectomized pa-
tients and healthy control subjects19.
Two of our patients have undergone thymectomy and 
only one presented positive ANA (patient 3); interestingly, 
this was the only one that evolved to a recurrent dd. This 
patient resembles those reported by Kister et al.9, who 
suggested that unspecific immune dysregulation, either 
due to thymectomy or genetic susceptibility might influ-
ence the development of a second autoimmune disease. 
Although all our patients achieved a good control of my-
asthenia symptoms, we could not determine the influence 
of developing dd on MG control due to the small num-
ber of patients in this series. Furthermore, in our service 
only 3 out of 630 patients with MG developed dd (0,5%), 
much less than the rate observed by Gotkine et al.10. While 
we evaluated 630 ambulatory patients, Gotkine et al sur-
veyed 214 patients that were admitted to the hospital, 
which does not reflect the whole population of patients 
with MG in a tertiary care center. This methodological 
difference may have left to selection bias of more severe 
patients, among them those with dd.
In conclusion, demyelinating diseases are rare among 
patients with MG and may be part of an autoimmune 
syndrome spectra or genetic predisposition to autoim-
munity. In this series of patients, only one developed a 
relapsing-remitting disease with positive low titer ANA 
and the others presented a monophasic course. As this 
is a small retrospective series, it was not possible to de-
termine whether dd was related to thymectomy and its 
potential impact on myasthenia gravis clinical control.
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